Skip to main content

Apolipoprotein E4 exaggerates diabetic dyslipidemia and atherosclerosis in mice lacking the LDL receptor.

Publication ,  Journal Article
Johnson, LA; Arbones-Mainar, JM; Fox, RG; Pendse, AA; Altenburg, MK; Kim, H-S; Maeda, N
Published in: Diabetes
September 2011

OBJECTIVE: We investigated the differential roles of apolipoprotein E (apoE) isoforms in modulating diabetic dyslipidemia-a potential cause of the increased cardiovascular disease risk of patients with diabetes. RESEARCH DESIGN AND METHODS: Diabetes was induced using streptozotocin (STZ) in human apoE3 (E3) or human apoE4 (E4) mice deficient in the LDL receptor (LDLR(-/-)). RESULTS: Diabetic E3LDLR(-/-) and E4LDLR(-/-) mice have indistinguishable levels of plasma glucose and insulin. Despite this, diabetes increased VLDL triglycerides and LDL cholesterol in E4LDLR(-/-) mice twice as much as in E3LDLR(-/-) mice. Diabetic E4LDLR(-/-) mice had similar lipoprotein fractional catabolic rates compared with diabetic E3LDLR(-/-) mice but had larger hepatic fat stores and increased VLDL secretion. Diabetic E4LDLR(-/-) mice demonstrated a decreased reliance on lipid as an energy source based on indirect calorimetry. Lower phosphorylated acetyl-CoA carboxylase content and higher gene expression of fatty acid synthase in the liver indicated reduced fatty acid oxidation and increased fatty acid synthesis. E4LDLR(-/-) primary hepatocytes cultured in high glucose accumulated more intracellular lipid than E3LDLR(-/-) hepatocytes concomitant with a 60% reduction in fatty acid oxidation. Finally, the exaggerated dyslipidemia in diabetic E4LDLR(-/-) mice was accompanied by a dramatic increase in atherosclerosis. CONCLUSIONS: ApoE4 causes severe dyslipidemia and atherosclerosis independent of its interaction with LDLR in a model of STZ-induced diabetes. ApoE4-expressing livers have reduced fatty acid oxidation, which contributes to the accumulation of tissue and plasma lipids.

Duke Scholars

Published In

Diabetes

DOI

EISSN

1939-327X

Publication Date

September 2011

Volume

60

Issue

9

Start / End Page

2285 / 2294

Location

United States

Related Subject Headings

  • Receptors, LDL
  • Mice, Transgenic
  • Mice
  • Male
  • Liver
  • Fatty Acids
  • Endocrinology & Metabolism
  • Dyslipidemias
  • Diabetes Mellitus, Experimental
  • Atherosclerosis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Johnson, L. A., Arbones-Mainar, J. M., Fox, R. G., Pendse, A. A., Altenburg, M. K., Kim, H.-S., & Maeda, N. (2011). Apolipoprotein E4 exaggerates diabetic dyslipidemia and atherosclerosis in mice lacking the LDL receptor. Diabetes, 60(9), 2285–2294. https://doi.org/10.2337/db11-0466
Johnson, Lance A., Jose M. Arbones-Mainar, Raymond G. Fox, Avani A. Pendse, Michael K. Altenburg, Hyung-Suk Kim, and Nobuyo Maeda. “Apolipoprotein E4 exaggerates diabetic dyslipidemia and atherosclerosis in mice lacking the LDL receptor.Diabetes 60, no. 9 (September 2011): 2285–94. https://doi.org/10.2337/db11-0466.
Johnson LA, Arbones-Mainar JM, Fox RG, Pendse AA, Altenburg MK, Kim H-S, et al. Apolipoprotein E4 exaggerates diabetic dyslipidemia and atherosclerosis in mice lacking the LDL receptor. Diabetes. 2011 Sep;60(9):2285–94.
Johnson, Lance A., et al. “Apolipoprotein E4 exaggerates diabetic dyslipidemia and atherosclerosis in mice lacking the LDL receptor.Diabetes, vol. 60, no. 9, Sept. 2011, pp. 2285–94. Pubmed, doi:10.2337/db11-0466.
Johnson LA, Arbones-Mainar JM, Fox RG, Pendse AA, Altenburg MK, Kim H-S, Maeda N. Apolipoprotein E4 exaggerates diabetic dyslipidemia and atherosclerosis in mice lacking the LDL receptor. Diabetes. 2011 Sep;60(9):2285–2294.

Published In

Diabetes

DOI

EISSN

1939-327X

Publication Date

September 2011

Volume

60

Issue

9

Start / End Page

2285 / 2294

Location

United States

Related Subject Headings

  • Receptors, LDL
  • Mice, Transgenic
  • Mice
  • Male
  • Liver
  • Fatty Acids
  • Endocrinology & Metabolism
  • Dyslipidemias
  • Diabetes Mellitus, Experimental
  • Atherosclerosis